Lennox-Gastaut Syndrome

Complex MONDO:0016532 Pathograph 10 Show in embeddings browser Epilepsy Neurodevelopmental Disorder Neurological Disease

Lennox-Gastaut syndrome (LGS) is a severe childhood-onset developmental and epileptic encephalopathy defined by a triad of multiple drug-resistant seizure types (notably tonic seizures, atonic/drop attacks, and atypical absences), a characteristic interictal EEG showing diffuse slow (<2.5 Hz) spike-and-wave complexes together with sleep-activated generalized paroxysmal fast activity, and cognitive impairment with behavioural problems. Onset is typically between ages 1 and 8 years (peak 3-5). LGS is etiologically heterogeneous: roughly two-thirds of cases are symptomatic of an identifiable structural, genetic, metabolic, or acquired brain insult, a substantial subset evolves from infantile spasms (West syndrome), and the remainder are of unknown cause. It is best understood as a shared, age-dependent electroclinical final common pathway of diffuse thalamocortical network dysfunction rather than a single disease with a single mechanism.

Ask OpenScientist

Ask a research question about Lennox-Gastaut Syndrome. OpenScientist will conduct autonomous deep research using the Disorder Mechanisms Knowledge Base and PubMed literature (typically 10-30 minutes).

Submitting...

Do not include personal health information in your question. Questions and results are cached in your browser's local storage.

🔗

Mappings

MONDO

MONDO:0016532 Lennox-Gastaut syndrome

MONDO:0016532 is the current Lennox-Gastaut syndrome disease concept.

Discussions and Knowledge Gaps

Is Lennox-Gastaut syndrome a single disease with a unifying network mechanism, or a convergent electroclinical endpoint that many distinct etiologies reach when they perturb the immature brain — and what network property, if any, actually defines membership?

CONTROVERSY OPEN gap_lgs_convergent_syndrome_vs_disease

Attached to

pathophysiology#Heterogeneous Etiologic Brain Insult pathophysiology#Diffuse Thalamocortical Network Dysfunction

LGS is defined by a characteristic triad that appears despite highly diverse structural, genetic, and metabolic causes, which is why this entry models a heterogeneous insult converging on a shared network node rather than a single lesion. Whether there is a genuine unifying mechanism (a specific thalamocortical network signature that all cases share) or whether LGS is essentially a stereotyped way the immature network fails, with no deeper common cause, remains debated. The answer determines whether LGS should be modeled as one disease entity or as a syndromic label over many diseases, and whether a network-level therapeutic target could exist.

Proposed experiments

Cross-etiology network-signature comparison in LGS

EEG-functional MRI network comparison experiment

exp_lgs_shared_network_signature

Using simultaneous EEG and functional MRI across patients with LGS of distinct etiologies (structural, genetic, post-infantile-spasms), test whether slow spike-and-wave and paroxysmal fast activity recruit the same thalamocortical hubs regardless of cause, and whether a shared network signature separates LGS from other generalized epilepsies.

Readouts

Shared network recruitment

pathophysiology#Diffuse Thalamocortical Network Dysfunction

functional magnetic resonance imaging assay electroencephalography

Direction: POSITIVE

Controls

Non-LGS generalized epilepsy comparators

Patients with other generalized epilepsies imaged under the same protocol.

Decision criterion

A unifying-mechanism interpretation is supported if a common thalamocortical network is recruited across etiologies and distinguishes LGS from comparators; a purely convergent-label interpretation is favored if the network signature tracks etiology rather than the LGS diagnosis.

Would support

pathophysiology#Diffuse Thalamocortical Network Dysfunction

Show evidence (1 reference)

PMID:24902608 SUPPORT Human Clinical

"We previously found common cerebral networks involved during slow spike-and-wave (SSW) and generalized paroxysmal fast activity (PFA), characteristic interictal discharges."

Supports a shared-network view by showing common cerebral networks engaged by the defining discharges across patients, the empirical basis for the convergent-syndrome position.

What circuit generates the tonic seizures and their electrographic correlate, sleep-activated generalized paroxysmal fast activity — the near-specific hallmark of LGS — and why is it activated by non-REM sleep?

KNOWLEDGE GAP OPEN gap_lgs_tonic_seizure_gpfa_circuit_mechanism

Attached to

pathophysiology#Generalized Paroxysmal Fast Activity and Tonic Seizure Generation

Generalized paroxysmal fast activity and tonic seizures are the most LGS-specific features, yet the circuit that produces them is poorly resolved. Competing accounts implicate thalamocortical mechanisms, brainstem arousal systems, and a sleep-state gating that selectively activates the discharge in non-REM sleep. Resolving the generator matters directly for neuromodulation targeting (for example centromedian thalamic stimulation) and for understanding why the hallmark seizure type is sleep-activated.

Proposed experiments

Sleep-state localization of the paroxysmal fast activity generator

intracranial seizure-onset localization experiment

exp_lgs_gpfa_generator_localization

Combine intracranial or high-density scalp recordings with sleep staging and thalamic recording where available to localize the onset of paroxysmal fast activity and test whether non-REM sleep gates a thalamocortical or brainstem generator.

Readouts

Fast-activity onset localization by sleep state

pathophysiology#Generalized Paroxysmal Fast Activity and Tonic Seizure Generation

electroencephalography

Direction: POSITIVE

Controls

Wake-state recordings

Matched recordings during wakefulness to isolate the sleep-gating effect.

Decision criterion

A generator is supported if paroxysmal fast activity reproducibly arises from a defined thalamocortical or brainstem node under non-REM sleep and not during matched wakefulness.

Would support

pathophysiology#Generalized Paroxysmal Fast Activity and Tonic Seizure Generation

Show evidence (1 reference)

PMID:24902608 SUPPORT Human Clinical

"We previously found common cerebral networks involved during slow spike-and-wave (SSW) and generalized paroxysmal fast activity (PFA), characteristic interictal discharges."

Identifies the network engaged by paroxysmal fast activity but does not resolve the specific generator or the sleep-state gating, which is the open question.

How much of the cognitive impairment in LGS is driven by ongoing seizures and interictal epileptiform activity (and therefore potentially modifiable by seizure control) versus fixed injury from the underlying etiology?

KNOWLEDGE GAP OPEN gap_lgs_epileptic_encephalopathy_cognition_reversibility

Attached to

pathophysiology#Interictal Epileptiform Activity-Driven Cognitive Impairment pathophysiology#Cognitive Impairment and Developmental Plateau

The developmental and epileptic encephalopathy concept holds that the epileptic activity itself contributes to cognitive decline beyond the underlying cause. If a substantial fraction of the cognitive burden is activity-driven, then earlier and more complete seizure control could improve developmental outcome; if it is fixed etiologic injury, cognitive prognosis would be largely independent of seizure control. Because LGS is typically drug-resistant, this fraction has been very hard to estimate, and it is a central open question with direct therapeutic stakes.

Proposed experiments

Coupling of seizure/EEG burden to cognitive trajectory in LGS

longitudinal cohort coupling experiment

exp_lgs_seizure_control_cognition_coupling

In a prospective LGS cohort, relate quantitative interictal epileptiform burden and seizure frequency to longitudinal neurodevelopmental trajectory, and where an intervention achieves marked seizure reduction, test whether cognitive trajectory inflects independently of etiology.

Readouts

Cognitive trajectory versus epileptiform burden

pathophysiology#Cognitive Impairment and Developmental Plateau

neuropsychological assessment electroencephalography

Direction: POSITIVE

Controls

Etiology-stratified comparison

Stratify by etiology to separate activity-driven from fixed injury effects.

Decision criterion

An activity-driven contribution is supported if reductions in epileptiform burden are followed by improvement or stabilization of cognitive trajectory within etiology strata; a fixed-injury interpretation is favored if trajectory tracks etiology regardless of seizure control.

Would support

pathophysiology#Interictal Epileptiform Activity-Driven Cognitive Impairment

Can any animal model reproduce the convergent LGS electroclinical syndrome (tonic seizures with generalized paroxysmal fast activity plus slow spike-and-wave), or do current single-gene models only capture one etiologic entry point into the syndrome?

HUMAN MODEL MISMATCH OPEN gap_lgs_animal_model_convergent_syndrome_fidelity

Attached to

pathophysiology#Diffuse Thalamocortical Network Dysfunction pathophysiology#Generalized Paroxysmal Fast Activity and Tonic Seizure Generation

Because LGS is a convergent syndrome rather than a single-gene disease, a faithful model would need to reproduce the shared network phenotype, not just one causative lesion. Existing models (for example GABRB3 knock-in mice) recapitulate a single genetic etiology and some seizure features, but whether they reproduce the defining tonic-seizure and paroxysmal fast-activity network signature of human LGS is uncertain. This is a translational-validity gap, distinct from an absence of evidence: model data exist, but their fidelity to the convergent human syndrome is the open question.

Proposed experiments

Network-phenotype fidelity testing across LGS etiologic models

cross-model network phenotyping experiment

exp_lgs_model_network_phenotype_fidelity

Phenotype several distinct LGS etiologic models (a GABA-A receptor model, an mTOR/structural model, and a synaptic model) with the same sleep-EEG and network readouts used clinically, testing whether any reproduces tonic seizures with sleep-activated fast activity and slow spike-and-wave.

Readouts

Tonic seizure and fast-activity phenotype

pathophysiology#Generalized Paroxysmal Fast Activity and Tonic Seizure Generation

electroencephalography

Direction: POSITIVE

Controls

Wild-type littermates

Matched wild-type animals recorded under identical protocols.

Decision criterion

Human fidelity for a model is supported if it reproduces the sleep-activated paroxysmal fast activity and tonic seizure signature; models that show only isolated seizures without the network signature are flagged as capturing an etiologic entry point rather than the LGS syndrome.

Would support

pathophysiology#Diffuse Thalamocortical Network Dysfunction

Show evidence (1 reference)

PMID:23934111 SUPPORT Human Clinical

"GABRB3, with de novo mutations in four patients, and ALG13, with the same de novo mutation in two patients; both genes show clear statistical evidence of association with epileptic encephalopathy."

Identifies GABRB3 as an LGS-associated gene whose mouse models test a single etiology; the mismatch question is whether such single-gene models reproduce the convergent LGS network phenotype.

⚙

Pathophysiology

Heterogeneous Etiologic Brain Insult

LGS is not caused by a single lesion. A structurally, genetically, metabolically, or acquired-injury-based insult to the developing brain (e.g., hypoxic-ischemic encephalopathy, cortical malformation, tuberous sclerosis, CNS infection, or a monogenic developmental and epileptic encephalopathy variant) supplies the upstream cause. This node captures the single concept of the initiating brain insult; its diverse specific causes converge downstream on a shared network disorder.

Neuron CL:0000540

Downstream

Age-Dependent Evolution from Infantile Spasms In a subset of children the same insult first manifests as infantile spasms and later transitions to the LGS electroclinical pattern.

Diffuse Thalamocortical Network Dysfunction Regardless of specific cause, the insult produces a diffusely dysfunctional thalamocortical network that generates the LGS phenotype.

Age-Dependent Evolution from Infantile Spasms

In roughly a fifth to a third of patients, LGS emerges from a prior diagnosis of infantile spasms (West syndrome) as the developing brain's epileptic expression shifts with maturation. This node captures the single concept of the age-dependent syndrome transition, a distinctive route into LGS separate from de novo presentation.

Neuron CL:0000540

Downstream

Diffuse Thalamocortical Network Dysfunction The maturational transition consolidates into the diffuse thalamocortical network dysfunction underlying LGS.

Diffuse Thalamocortical Network Dysfunction

LGS behaves as a secondary network ("secondary generalized") epilepsy in which widespread, bilaterally synchronous epileptic activity is generated by a diffusely dysfunctional thalamocortical network rather than by a single cortical focus. This node captures the single concept of the network-level substrate that unifies the heterogeneous etiologies.

Neuron CL:0000540

Downstream

Cortical Excitation-Inhibition Imbalance Network dysfunction expresses locally as a shift toward excitation over inhibition in cortical circuits.

Show evidence (1 reference)

PMID:24902608 SUPPORT Human Clinical

"We previously found common cerebral networks involved during slow spike-and-wave (SSW) and generalized paroxysmal fast activity (PFA), characteristic interictal discharges."

Neuroimaging evidence that the characteristic LGS discharges engage a shared cerebral network across etiologies, supporting the secondary network model in which a diffusely dysfunctional network, not a single focus, generates the phenotype.

Cortical Excitation-Inhibition Imbalance

Within the dysfunctional network, the balance between synaptic excitation and GABAergic inhibition is shifted toward excitation, lowering the threshold for hypersynchronous discharges. This node captures the single concept of the excitation-inhibition imbalance and conforms to the shared epilepsy final common pathway.

GABAergic interneuron CL:0000617

Regulation of GABAergic synaptic transmission GO:0032228 ↓ DECREASED

Downstream

Slow Spike-and-Wave Discharge Generation The imbalance supports the corticothalamic oscillation seen as slow spike-and-wave activity.

Generalized Paroxysmal Fast Activity and Tonic Seizure Generation The imbalance also enables the sleep-activated fast-activity discharges that underlie tonic seizures.

Slow Spike-and-Wave Discharge Generation

A defining electrographic feature of LGS is the diffuse slow (<2.5 Hz) spike-and-wave complex, reflecting pathological corticothalamic oscillation. This node captures the single concept of slow spike-and-wave generation, the substrate of atypical absence seizures.

Neuron CL:0000540

Downstream

Multiple Drug-Resistant Seizure Types Slow spike-and-wave discharges manifest clinically as atypical absence seizures within the LGS seizure repertoire.

Generalized Paroxysmal Fast Activity and Tonic Seizure Generation

The second defining electrographic feature is sleep-activated generalized paroxysmal fast activity (GPFA), the correlate of tonic seizures, which are the most characteristic seizure type of LGS and predominate in non-REM sleep. This node captures the single concept of fast-activity/tonic seizure generation.

Neuron CL:0000540

Downstream

Atonic Drop Attack Generation Tonic and related discharges contribute to sudden tone changes producing drop attacks.

Multiple Drug-Resistant Seizure Types Fast-activity discharges manifest clinically as tonic seizures.

Atonic Drop Attack Generation

Sudden loss (atonic) or brief increase (tonic) of postural tone produces drop attacks (astatic seizures), a major source of injury in LGS. This node captures the single concept of drop-attack generation, distinct from the tonic and absence seizure mechanisms above.

Neuron CL:0000540

Downstream

Multiple Drug-Resistant Seizure Types Drop attacks are one of the multiple drug-resistant seizure types comprising the syndrome.

Interictal Epileptiform Activity-Driven Cognitive Impairment

LGS is a developmental and epileptic encephalopathy: beyond any cognitive effect of the underlying cause, the frequent seizures and near-continuous interictal epileptiform activity are themselves thought to impair cognitive development and drive stagnation or regression. This node captures the single concept of the epileptic-encephalopathy contribution to cognition.

Neuron CL:0000540

Downstream

Cognitive Impairment and Developmental Plateau Ongoing epileptiform activity contributes to the cognitive plateau and regression characteristic of the syndrome.

Multiple Drug-Resistant Seizure Types

The clinical hallmark of LGS is the co-occurrence of several seizure types in one child, characteristically tonic, atonic, and atypical absence seizures, that are typically resistant to antiseizure medications. This node captures the single concept of the multiple-drug-resistant-seizure endpoint and conforms to the shared epilepsy final common pathway.

Neuron CL:0000540

Cognitive Impairment and Developmental Plateau

Most children with LGS develop intellectual disability with developmental plateau or regression and frequent behavioural problems. This node captures the single concept of the cognitive/developmental outcome, the endpoint of both the underlying etiology and the epileptic encephalopathy.

Neuron CL:0000540

⬡

Pathograph

Use the checkboxes to hide or show graph categories. Hover nodes for evidence and cross-linked metadata.

●

Phenotypes

Nervous System 5

Atypical Absence Seizures Atypical absence seizure HP:0007270

Intellectual Disability Intellectual disability HP:0001249

Generalized Tonic-Clonic Seizures Bilateral tonic-clonic seizure HP:0002069

Global Developmental Delay Global developmental delay HP:0001263

Behavioral Abnormalities Atypical behavior HP:0000708

Other 5

Tonic Seizures Generalized tonic seizure HP:0010818

Atonic Seizures (Drop Attacks) Atonic seizure HP:0010819

Epileptic Encephalopathy Epileptic encephalopathy HP:0200134

Myoclonic Seizures Myoclonic seizure HP:0032794

Nonconvulsive Status Epilepticus Status epilepticus HP:0002133

🧬

Genetic Associations

Genetically heterogeneous developmental and epileptic encephalopathy genes

Show evidence (2 references)

PMID:23934111 SUPPORT Human Clinical

"de novo mutations in patients with two classical epileptic encephalopathies: infantile spasms (n = 149) and Lennox-Gastaut syndrome (n = 115)."

The Epi4K trio-exome study established that a substantial fraction of LGS is caused by de novo variants, sequencing 115 LGS probands alongside infantile spasms cases.

PMID:23934111 SUPPORT Human Clinical

"GABRB3, with de novo mutations in four patients, and ALG13, with the same de novo mutation in two patients; both genes show clear statistical evidence of association with epileptic encephalopathy."

Identifies GABRB3 and ALG13 as genome-wide-significant developmental and epileptic encephalopathy genes in the IS/LGS cohort, illustrating the genetic heterogeneity of LGS.

💊

Medical Actions

Broad-Spectrum Antiseizure Medication

Action: Pharmacotherapy NCIT:C15986

First-line pharmacotherapy uses broad-spectrum antiseizure medications (e.g., valproate, lamotrigine); LGS seizures are typically drug-resistant and require combination therapy. Narrow-spectrum sodium-channel blockers (carbamazepine, oxcarbazepine, phenytoin) and vigabatrin can aggravate atypical absence and myoclonic seizures and are generally avoided.

LGS-Indicated Adjunctive Antiseizure Agents

Action: Pharmacotherapy NCIT:C15986

Agent: cannabidiol CHEBI:69478 fenfluramine CHEBI:5000 rufinamide CHEBI:134966 clobazam CHEBI:31413

Several agents are specifically approved as adjunctive therapy for LGS-associated seizures, including rufinamide, clobazam, felbamate, topiramate, cannabidiol, and fenfluramine.

Show evidence (1 reference)

PMID:29768152 SUPPORT Human Clinical

"median percent reduction from baseline in drop-seizure frequency during the treatment period was 41.9% in the 20-mg cannabidiol group"

Randomized placebo-controlled trial (GWPCARE3) demonstrating that add-on cannabidiol reduces drop-seizure frequency in LGS, supporting its role as an LGS-indicated adjunctive agent.

Ketogenic Diet Therapy

Action: ketogenic diet intake Ontology label: Ketogenic Diet NCIT:C173168

Ketogenic and modified Atkins diets are used for drug-resistant LGS seizures.

Corpus Callosotomy

Action: surgical procedure Ontology label: Surgical Procedure NCIT:C15329

Palliative corpus callosotomy is used to reduce drop attacks (tonic/atonic seizures) refractory to medication.

Vagus Nerve Stimulation

Action: surgical procedure Ontology label: Surgical Procedure NCIT:C15329

Vagus nerve stimulation is a palliative neuromodulation option for drug-resistant LGS.

{ }

Source YAML

click to show

name: Lennox-Gastaut Syndrome
creation_date: "2026-07-17T00:00:00Z"
category: Complex
description: >-
  Lennox-Gastaut syndrome (LGS) is a severe childhood-onset developmental and
  epileptic encephalopathy defined by a triad of multiple drug-resistant seizure
  types (notably tonic seizures, atonic/drop attacks, and atypical absences), a
  characteristic interictal EEG showing diffuse slow (<2.5 Hz) spike-and-wave
  complexes together with sleep-activated generalized paroxysmal fast activity,
  and cognitive impairment with behavioural problems. Onset is typically between
  ages 1 and 8 years (peak 3-5). LGS is etiologically heterogeneous: roughly
  two-thirds of cases are symptomatic of an identifiable structural, genetic,
  metabolic, or acquired brain insult, a substantial subset evolves from
  infantile spasms (West syndrome), and the remainder are of unknown cause. It
  is best understood as a shared, age-dependent electroclinical final common
  pathway of diffuse thalamocortical network dysfunction rather than a single
  disease with a single mechanism.
parents:
- Epilepsy
- Neurodevelopmental Disorder
- Neurological Disease
synonyms:
- LGS
- Lennox syndrome
- Epileptic encephalopathy with diffuse slow spike-and-wave
disease_term:
  preferred_term: Lennox-Gastaut syndrome
  term:
    id: MONDO:0016532
    label: Lennox-Gastaut syndrome
mappings:
  mondo_mappings:
  - term:
      id: MONDO:0016532
      label: Lennox-Gastaut syndrome
    mapping_predicate: skos:exactMatch
    mapping_source: MONDO
    mapping_justification: >-
      MONDO:0016532 is the current Lennox-Gastaut syndrome disease concept.
pathophysiology:
- name: Heterogeneous Etiologic Brain Insult
  description: >-
    LGS is not caused by a single lesion. A structurally, genetically,
    metabolically, or acquired-injury-based insult to the developing brain
    (e.g., hypoxic-ischemic encephalopathy, cortical malformation, tuberous
    sclerosis, CNS infection, or a monogenic developmental and epileptic
    encephalopathy variant) supplies the upstream cause. This node captures the
    single concept of the initiating brain insult; its diverse specific causes
    converge downstream on a shared network disorder.
  role: trigger
  cell_types:
  - preferred_term: Neuron
    term:
      id: CL:0000540
      label: neuron
  downstream:
  - target: Age-Dependent Evolution from Infantile Spasms
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    description: >-
      In a subset of children the same insult first manifests as infantile
      spasms and later transitions to the LGS electroclinical pattern.
  - target: Diffuse Thalamocortical Network Dysfunction
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    description: >-
      Regardless of specific cause, the insult produces a diffusely dysfunctional
      thalamocortical network that generates the LGS phenotype.
- name: Age-Dependent Evolution from Infantile Spasms
  description: >-
    In roughly a fifth to a third of patients, LGS emerges from a prior
    diagnosis of infantile spasms (West syndrome) as the developing brain's
    epileptic expression shifts with maturation. This node captures the single
    concept of the age-dependent syndrome transition, a distinctive route into
    LGS separate from de novo presentation.
  role: mediator
  cell_types:
  - preferred_term: Neuron
    term:
      id: CL:0000540
      label: neuron
  downstream:
  - target: Diffuse Thalamocortical Network Dysfunction
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    description: >-
      The maturational transition consolidates into the diffuse thalamocortical
      network dysfunction underlying LGS.
- name: Diffuse Thalamocortical Network Dysfunction
  description: >-
    LGS behaves as a secondary network ("secondary generalized") epilepsy in
    which widespread, bilaterally synchronous epileptic activity is generated by
    a diffusely dysfunctional thalamocortical network rather than by a single
    cortical focus. This node captures the single concept of the network-level
    substrate that unifies the heterogeneous etiologies.
  role: mediator
  cell_types:
  - preferred_term: Neuron
    term:
      id: CL:0000540
      label: neuron
  evidence:
  - reference: PMID:24902608
    reference_title: "Lennox-Gastaut syndrome and phenotype: secondary network epilepsies."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "We previously found common cerebral networks involved during slow spike-and-wave (SSW) and generalized paroxysmal fast activity (PFA), characteristic interictal discharges."
    explanation: >-
      Neuroimaging evidence that the characteristic LGS discharges engage a
      shared cerebral network across etiologies, supporting the secondary
      network model in which a diffusely dysfunctional network, not a single
      focus, generates the phenotype.
  downstream:
  - target: Cortical Excitation-Inhibition Imbalance
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    description: >-
      Network dysfunction expresses locally as a shift toward excitation over
      inhibition in cortical circuits.
- name: Cortical Excitation-Inhibition Imbalance
  description: >-
    Within the dysfunctional network, the balance between synaptic excitation
    and GABAergic inhibition is shifted toward excitation, lowering the threshold
    for hypersynchronous discharges. This node captures the single concept of
    the excitation-inhibition imbalance and conforms to the shared epilepsy
    final common pathway.
  role: mediator
  conforms_to: "epilepsy_excitation_inhibition_imbalance#Excitation-Inhibition Imbalance"
  cell_types:
  - preferred_term: GABAergic interneuron
    term:
      id: CL:0000617
      label: GABAergic neuron
  biological_processes:
  - preferred_term: Regulation of GABAergic synaptic transmission
    term:
      id: GO:0032228
      label: regulation of synaptic transmission, GABAergic
    modifier: DECREASED
  downstream:
  - target: Slow Spike-and-Wave Discharge Generation
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    description: >-
      The imbalance supports the corticothalamic oscillation seen as slow
      spike-and-wave activity.
  - target: Generalized Paroxysmal Fast Activity and Tonic Seizure Generation
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    description: >-
      The imbalance also enables the sleep-activated fast-activity discharges
      that underlie tonic seizures.
- name: Slow Spike-and-Wave Discharge Generation
  description: >-
    A defining electrographic feature of LGS is the diffuse slow (<2.5 Hz)
    spike-and-wave complex, reflecting pathological corticothalamic oscillation.
    This node captures the single concept of slow spike-and-wave generation, the
    substrate of atypical absence seizures.
  role: central_effector
  cell_types:
  - preferred_term: Neuron
    term:
      id: CL:0000540
      label: neuron
  downstream:
  - target: Multiple Drug-Resistant Seizure Types
    causal_link_type: DIRECT
    description: >-
      Slow spike-and-wave discharges manifest clinically as atypical absence
      seizures within the LGS seizure repertoire.
- name: Generalized Paroxysmal Fast Activity and Tonic Seizure Generation
  description: >-
    The second defining electrographic feature is sleep-activated generalized
    paroxysmal fast activity (GPFA), the correlate of tonic seizures, which are
    the most characteristic seizure type of LGS and predominate in non-REM
    sleep. This node captures the single concept of fast-activity/tonic seizure
    generation.
  role: central_effector
  cell_types:
  - preferred_term: Neuron
    term:
      id: CL:0000540
      label: neuron
  downstream:
  - target: Atonic Drop Attack Generation
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    description: >-
      Tonic and related discharges contribute to sudden tone changes producing
      drop attacks.
  - target: Multiple Drug-Resistant Seizure Types
    causal_link_type: DIRECT
    description: >-
      Fast-activity discharges manifest clinically as tonic seizures.
- name: Atonic Drop Attack Generation
  description: >-
    Sudden loss (atonic) or brief increase (tonic) of postural tone produces
    drop attacks (astatic seizures), a major source of injury in LGS. This node
    captures the single concept of drop-attack generation, distinct from the
    tonic and absence seizure mechanisms above.
  role: effector
  cell_types:
  - preferred_term: Neuron
    term:
      id: CL:0000540
      label: neuron
  downstream:
  - target: Multiple Drug-Resistant Seizure Types
    causal_link_type: DIRECT
    description: >-
      Drop attacks are one of the multiple drug-resistant seizure types
      comprising the syndrome.
- name: Interictal Epileptiform Activity-Driven Cognitive Impairment
  description: >-
    LGS is a developmental and epileptic encephalopathy: beyond any cognitive
    effect of the underlying cause, the frequent seizures and near-continuous
    interictal epileptiform activity are themselves thought to impair cognitive
    development and drive stagnation or regression. This node captures the single
    concept of the epileptic-encephalopathy contribution to cognition.
  role: mediator
  cell_types:
  - preferred_term: Neuron
    term:
      id: CL:0000540
      label: neuron
  downstream:
  - target: Cognitive Impairment and Developmental Plateau
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    description: >-
      Ongoing epileptiform activity contributes to the cognitive plateau and
      regression characteristic of the syndrome.
- name: Multiple Drug-Resistant Seizure Types
  description: >-
    The clinical hallmark of LGS is the co-occurrence of several seizure types
    in one child, characteristically tonic, atonic, and atypical absence
    seizures, that are typically resistant to antiseizure medications. This node
    captures the single concept of the multiple-drug-resistant-seizure endpoint
    and conforms to the shared epilepsy final common pathway.
  role: consequence
  conforms_to: "epilepsy_excitation_inhibition_imbalance#Recurrent Unprovoked Seizures"
  cell_types:
  - preferred_term: Neuron
    term:
      id: CL:0000540
      label: neuron
- name: Cognitive Impairment and Developmental Plateau
  description: >-
    Most children with LGS develop intellectual disability with developmental
    plateau or regression and frequent behavioural problems. This node captures
    the single concept of the cognitive/developmental outcome, the endpoint of
    both the underlying etiology and the epileptic encephalopathy.
  role: consequence
  cell_types:
  - preferred_term: Neuron
    term:
      id: CL:0000540
      label: neuron
phenotypes:
- name: Tonic Seizures
  description: >-
    Tonic seizures, often nocturnal and sleep-activated, are the most
    characteristic seizure type of LGS.
  phenotype_term:
    preferred_term: Generalized tonic seizure
    term:
      id: HP:0010818
      label: Generalized tonic seizure
- name: Atonic Seizures (Drop Attacks)
  description: >-
    Atonic (astatic) seizures cause sudden loss of postural tone and drop
    attacks with frequent falls and injuries.
  phenotype_term:
    preferred_term: Atonic seizure
    term:
      id: HP:0010819
      label: Atonic seizure
- name: Atypical Absence Seizures
  description: >-
    Atypical absences with gradual onset/offset and incomplete loss of awareness
    accompany the slow spike-and-wave EEG pattern.
  phenotype_term:
    preferred_term: Atypical absence seizure
    term:
      id: HP:0007270
      label: Atypical absence seizure
- name: Epileptic Encephalopathy
  description: >-
    Frequent seizures and abundant interictal epileptiform activity constitute
    an epileptic encephalopathy contributing to cognitive impairment.
  phenotype_term:
    preferred_term: Epileptic encephalopathy
    term:
      id: HP:0200134
      label: Epileptic encephalopathy
- name: Intellectual Disability
  description: >-
    Most affected children have intellectual disability with developmental
    plateau or regression.
  phenotype_term:
    preferred_term: Intellectual disability
    term:
      id: HP:0001249
      label: Intellectual disability
- name: Myoclonic Seizures
  description: >-
    Myoclonic seizures are a common additional seizure type in the LGS seizure
    repertoire.
  phenotype_term:
    preferred_term: Myoclonic seizure
    term:
      id: HP:0032794
      label: Myoclonic seizure
- name: Generalized Tonic-Clonic Seizures
  description: >-
    Generalized (bilateral) tonic-clonic seizures occur commonly in addition to
    the defining seizure types.
  phenotype_term:
    preferred_term: Generalized tonic-clonic seizure
    term:
      id: HP:0002069
      label: Bilateral tonic-clonic seizure
- name: Nonconvulsive Status Epilepticus
  description: >-
    Episodes of nonconvulsive status epilepticus (often with tonic and atypical
    absence features) occur in a large fraction of patients over the disease
    course.
  phenotype_term:
    preferred_term: Nonconvulsive status epilepticus
    term:
      id: HP:0002133
      label: Status epilepticus
- name: Global Developmental Delay
  description: >-
    Global developmental delay frequently precedes or accompanies seizure onset
    and evolves into intellectual disability.
  phenotype_term:
    preferred_term: Global developmental delay
    term:
      id: HP:0001263
      label: Global developmental delay
- name: Behavioral Abnormalities
  description: >-
    Behavioral problems, including hyperactivity, aggression, and autistic
    features, are common and add to the disability burden.
  phenotype_term:
    preferred_term: Behavioral abnormality
    term:
      id: HP:0000708
      label: Atypical behavior
genetic:
- name: Genetically heterogeneous developmental and epileptic encephalopathy genes
  notes: >-
    LGS has no single causative gene. A minority of cases carry pathogenic
    variants in developmental and epileptic encephalopathy genes (reported
    examples include SCN1A, SCN2A, SCN8A, STXBP1, CHD2, DNM1, GABRB3, FOXG1,
    ALG13, and others); many cases are structural or of unknown cause. Most
    cases are sporadic, and when monogenic the causative variants are typically
    de novo. Contributing genes are named here rather than asserting a single
    Mendelian locus.
  evidence:
  - reference: PMID:23934111
    reference_title: "De novo mutations in epileptic encephalopathies."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "de novo mutations in patients with two classical epileptic encephalopathies: infantile spasms (n = 149) and Lennox-Gastaut syndrome (n = 115)."
    explanation: >-
      The Epi4K trio-exome study established that a substantial fraction of LGS
      is caused by de novo variants, sequencing 115 LGS probands alongside
      infantile spasms cases.
  - reference: PMID:23934111
    reference_title: "De novo mutations in epileptic encephalopathies."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "GABRB3, with de novo mutations in four patients, and ALG13, with the same de novo mutation in two patients; both genes show clear statistical evidence of association with epileptic encephalopathy."
    explanation: >-
      Identifies GABRB3 and ALG13 as genome-wide-significant developmental and
      epileptic encephalopathy genes in the IS/LGS cohort, illustrating the
      genetic heterogeneity of LGS.
treatments:
- name: Broad-Spectrum Antiseizure Medication
  description: >-
    First-line pharmacotherapy uses broad-spectrum antiseizure medications
    (e.g., valproate, lamotrigine); LGS seizures are typically drug-resistant and
    require combination therapy. Narrow-spectrum sodium-channel blockers
    (carbamazepine, oxcarbazepine, phenytoin) and vigabatrin can aggravate
    atypical absence and myoclonic seizures and are generally avoided.
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
- name: LGS-Indicated Adjunctive Antiseizure Agents
  description: >-
    Several agents are specifically approved as adjunctive therapy for
    LGS-associated seizures, including rufinamide, clobazam, felbamate,
    topiramate, cannabidiol, and fenfluramine.
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
    therapeutic_agent:
    - preferred_term: cannabidiol
      term:
        id: CHEBI:69478
        label: cannabidiol
    - preferred_term: fenfluramine
      term:
        id: CHEBI:5000
        label: fenfluramine
    - preferred_term: rufinamide
      term:
        id: CHEBI:134966
        label: rufinamide
    - preferred_term: clobazam
      term:
        id: CHEBI:31413
        label: clobazam
  evidence:
  - reference: PMID:29768152
    reference_title: "Effect of Cannabidiol on Drop Seizures in the Lennox-Gastaut Syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "median percent reduction from baseline in drop-seizure frequency during the treatment period was 41.9% in the 20-mg cannabidiol group"
    explanation: >-
      Randomized placebo-controlled trial (GWPCARE3) demonstrating that add-on
      cannabidiol reduces drop-seizure frequency in LGS, supporting its role as
      an LGS-indicated adjunctive agent.
- name: Ketogenic Diet Therapy
  description: >-
    Ketogenic and modified Atkins diets are used for drug-resistant LGS seizures.
  treatment_term:
    preferred_term: ketogenic diet intake
    term:
      id: NCIT:C173168
      label: Ketogenic Diet
- name: Corpus Callosotomy
  description: >-
    Palliative corpus callosotomy is used to reduce drop attacks (tonic/atonic
    seizures) refractory to medication.
  treatment_term:
    preferred_term: surgical procedure
    term:
      id: NCIT:C15329
      label: Surgical Procedure
- name: Vagus Nerve Stimulation
  description: >-
    Vagus nerve stimulation is a palliative neuromodulation option for
    drug-resistant LGS.
  treatment_term:
    preferred_term: surgical procedure
    term:
      id: NCIT:C15329
      label: Surgical Procedure
datasets: []
discussions:
- discussion_id: gap_lgs_convergent_syndrome_vs_disease
  prompt: >-
    Is Lennox-Gastaut syndrome a single disease with a unifying network
    mechanism, or a convergent electroclinical endpoint that many distinct
    etiologies reach when they perturb the immature brain — and what network
    property, if any, actually defines membership?
  kind: CONTROVERSY
  status: OPEN
  attaches_to:
  - pathophysiology#Heterogeneous Etiologic Brain Insult
  - pathophysiology#Diffuse Thalamocortical Network Dysfunction
  rationale: >-
    LGS is defined by a characteristic triad that appears despite highly
    diverse structural, genetic, and metabolic causes, which is why this entry
    models a heterogeneous insult converging on a shared network node rather
    than a single lesion. Whether there is a genuine unifying mechanism (a
    specific thalamocortical network signature that all cases share) or whether
    LGS is essentially a stereotyped way the immature network fails, with no
    deeper common cause, remains debated. The answer determines whether LGS
    should be modeled as one disease entity or as a syndromic label over many
    diseases, and whether a network-level therapeutic target could exist.
  evidence:
  - reference: PMID:24902608
    reference_title: "Lennox-Gastaut syndrome and phenotype: secondary network epilepsies."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "We previously found common cerebral networks involved during slow spike-and-wave (SSW) and generalized paroxysmal fast activity (PFA), characteristic interictal discharges."
    explanation: >-
      Supports a shared-network view by showing common cerebral networks engaged
      by the defining discharges across patients, the empirical basis for the
      convergent-syndrome position.
  proposed_experiments:
  - experiment_id: exp_lgs_shared_network_signature
    name: Cross-etiology network-signature comparison in LGS
    description: >-
      Using simultaneous EEG and functional MRI across patients with LGS of
      distinct etiologies (structural, genetic, post-infantile-spasms), test
      whether slow spike-and-wave and paroxysmal fast activity recruit the same
      thalamocortical hubs regardless of cause, and whether a shared network
      signature separates LGS from other generalized epilepsies.
    experiment_type:
      preferred_term: EEG-functional MRI network comparison experiment
    readouts:
    - name: Shared network recruitment
      target: pathophysiology#Diffuse Thalamocortical Network Dysfunction
      assays:
      - preferred_term: functional magnetic resonance imaging assay
      - preferred_term: electroencephalography
      direction: POSITIVE
    controls:
    - name: Non-LGS generalized epilepsy comparators
      description: Patients with other generalized epilepsies imaged under the same protocol.
    decision_criterion: >-
      A unifying-mechanism interpretation is supported if a common
      thalamocortical network is recruited across etiologies and distinguishes
      LGS from comparators; a purely convergent-label interpretation is favored
      if the network signature tracks etiology rather than the LGS diagnosis.
    would_support:
    - pathophysiology#Diffuse Thalamocortical Network Dysfunction

- discussion_id: gap_lgs_tonic_seizure_gpfa_circuit_mechanism
  prompt: >-
    What circuit generates the tonic seizures and their electrographic
    correlate, sleep-activated generalized paroxysmal fast activity — the
    near-specific hallmark of LGS — and why is it activated by non-REM sleep?
  kind: KNOWLEDGE_GAP
  status: OPEN
  attaches_to:
  - pathophysiology#Generalized Paroxysmal Fast Activity and Tonic Seizure Generation
  rationale: >-
    Generalized paroxysmal fast activity and tonic seizures are the most
    LGS-specific features, yet the circuit that produces them is poorly
    resolved. Competing accounts implicate thalamocortical mechanisms, brainstem
    arousal systems, and a sleep-state gating that selectively activates the
    discharge in non-REM sleep. Resolving the generator matters directly for
    neuromodulation targeting (for example centromedian thalamic stimulation)
    and for understanding why the hallmark seizure type is sleep-activated.
  evidence:
  - reference: PMID:24902608
    reference_title: "Lennox-Gastaut syndrome and phenotype: secondary network epilepsies."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "We previously found common cerebral networks involved during slow spike-and-wave (SSW) and generalized paroxysmal fast activity (PFA), characteristic interictal discharges."
    explanation: >-
      Identifies the network engaged by paroxysmal fast activity but does not
      resolve the specific generator or the sleep-state gating, which is the
      open question.
  proposed_experiments:
  - experiment_id: exp_lgs_gpfa_generator_localization
    name: Sleep-state localization of the paroxysmal fast activity generator
    description: >-
      Combine intracranial or high-density scalp recordings with sleep staging
      and thalamic recording where available to localize the onset of
      paroxysmal fast activity and test whether non-REM sleep gates a
      thalamocortical or brainstem generator.
    experiment_type:
      preferred_term: intracranial seizure-onset localization experiment
    readouts:
    - name: Fast-activity onset localization by sleep state
      target: pathophysiology#Generalized Paroxysmal Fast Activity and Tonic Seizure Generation
      assays:
      - preferred_term: electroencephalography
      direction: POSITIVE
    controls:
    - name: Wake-state recordings
      description: Matched recordings during wakefulness to isolate the sleep-gating effect.
    decision_criterion: >-
      A generator is supported if paroxysmal fast activity reproducibly arises
      from a defined thalamocortical or brainstem node under non-REM sleep and
      not during matched wakefulness.
    would_support:
    - pathophysiology#Generalized Paroxysmal Fast Activity and Tonic Seizure Generation

- discussion_id: gap_lgs_epileptic_encephalopathy_cognition_reversibility
  prompt: >-
    How much of the cognitive impairment in LGS is driven by ongoing seizures
    and interictal epileptiform activity (and therefore potentially modifiable
    by seizure control) versus fixed injury from the underlying etiology?
  kind: KNOWLEDGE_GAP
  status: OPEN
  attaches_to:
  - pathophysiology#Interictal Epileptiform Activity-Driven Cognitive Impairment
  - pathophysiology#Cognitive Impairment and Developmental Plateau
  rationale: >-
    The developmental and epileptic encephalopathy concept holds that the
    epileptic activity itself contributes to cognitive decline beyond the
    underlying cause. If a substantial fraction of the cognitive burden is
    activity-driven, then earlier and more complete seizure control could
    improve developmental outcome; if it is fixed etiologic injury, cognitive
    prognosis would be largely independent of seizure control. Because LGS is
    typically drug-resistant, this fraction has been very hard to estimate, and
    it is a central open question with direct therapeutic stakes.
  proposed_experiments:
  - experiment_id: exp_lgs_seizure_control_cognition_coupling
    name: Coupling of seizure/EEG burden to cognitive trajectory in LGS
    description: >-
      In a prospective LGS cohort, relate quantitative interictal
      epileptiform burden and seizure frequency to longitudinal
      neurodevelopmental trajectory, and where an intervention achieves marked
      seizure reduction, test whether cognitive trajectory inflects
      independently of etiology.
    experiment_type:
      preferred_term: longitudinal cohort coupling experiment
    readouts:
    - name: Cognitive trajectory versus epileptiform burden
      target: pathophysiology#Cognitive Impairment and Developmental Plateau
      assays:
      - preferred_term: neuropsychological assessment
      - preferred_term: electroencephalography
      direction: POSITIVE
    controls:
    - name: Etiology-stratified comparison
      description: Stratify by etiology to separate activity-driven from fixed injury effects.
    decision_criterion: >-
      An activity-driven contribution is supported if reductions in epileptiform
      burden are followed by improvement or stabilization of cognitive
      trajectory within etiology strata; a fixed-injury interpretation is
      favored if trajectory tracks etiology regardless of seizure control.
    would_support:
    - pathophysiology#Interictal Epileptiform Activity-Driven Cognitive Impairment

- discussion_id: gap_lgs_animal_model_convergent_syndrome_fidelity
  prompt: >-
    Can any animal model reproduce the convergent LGS electroclinical syndrome
    (tonic seizures with generalized paroxysmal fast activity plus slow
    spike-and-wave), or do current single-gene models only capture one
    etiologic entry point into the syndrome?
  kind: HUMAN_MODEL_MISMATCH
  status: OPEN
  attaches_to:
  - pathophysiology#Diffuse Thalamocortical Network Dysfunction
  - pathophysiology#Generalized Paroxysmal Fast Activity and Tonic Seizure Generation
  rationale: >-
    Because LGS is a convergent syndrome rather than a single-gene disease, a
    faithful model would need to reproduce the shared network phenotype, not
    just one causative lesion. Existing models (for example GABRB3 knock-in
    mice) recapitulate a single genetic etiology and some seizure features, but
    whether they reproduce the defining tonic-seizure and paroxysmal
    fast-activity network signature of human LGS is uncertain. This is a
    translational-validity gap, distinct from an absence of evidence: model
    data exist, but their fidelity to the convergent human syndrome is the open
    question.
  evidence:
  - reference: PMID:23934111
    reference_title: "De novo mutations in epileptic encephalopathies."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "GABRB3, with de novo mutations in four patients, and ALG13, with the same de novo mutation in two patients; both genes show clear statistical evidence of association with epileptic encephalopathy."
    explanation: >-
      Identifies GABRB3 as an LGS-associated gene whose mouse models test a
      single etiology; the mismatch question is whether such single-gene models
      reproduce the convergent LGS network phenotype.
  proposed_experiments:
  - experiment_id: exp_lgs_model_network_phenotype_fidelity
    name: Network-phenotype fidelity testing across LGS etiologic models
    description: >-
      Phenotype several distinct LGS etiologic models (a GABA-A receptor model,
      an mTOR/structural model, and a synaptic model) with the same
      sleep-EEG and network readouts used clinically, testing whether any
      reproduces tonic seizures with sleep-activated fast activity and slow
      spike-and-wave.
    experiment_type:
      preferred_term: cross-model network phenotyping experiment
    readouts:
    - name: Tonic seizure and fast-activity phenotype
      target: pathophysiology#Generalized Paroxysmal Fast Activity and Tonic Seizure Generation
      assays:
      - preferred_term: electroencephalography
      direction: POSITIVE
    controls:
    - name: Wild-type littermates
      description: Matched wild-type animals recorded under identical protocols.
    decision_criterion: >-
      Human fidelity for a model is supported if it reproduces the sleep-activated
      paroxysmal fast activity and tonic seizure signature; models that show only
      isolated seizures without the network signature are flagged as capturing an
      etiologic entry point rather than the LGS syndrome.
    would_support:
    - pathophysiology#Diffuse Thalamocortical Network Dysfunction

📚

References & Deep Research

Deep Research

Claude Code ▸

1. Disease Information

claude-haiku-4-5-20251001, claude-opus-4-8 13 citations 2026-07-17T15:15:03.681936

1. Disease Information

Overview. Lennox-Gastaut Syndrome is a severe, childhood-onset developmental and epileptic encephalopathy (DEE) defined by a triad: 1. Multiple seizure types — obligatorily including tonic seizures (the hallmark, often nocturnal) plus atypical absences, atonic/drop attacks, and frequently myoclonic, generalized tonic-clonic, and nonconvulsive status epilepticus; 2. A characteristic EEG signature — diffuse slow spike-and-wave complexes (<2.5–3 Hz) in the awake state and bursts of generalized paroxysmal fast activity (GPFA, ~10–20 Hz) during sleep (GPFA is considered the electrographic correlate of tonic seizures and is near-specific for LGS); 3. Cognitive and behavioral impairment — intellectual disability that is usually progressive.

Seizures are characteristically drug-resistant, and the encephalopathy is lifelong. The 2022 ILAE syndrome classification for the first time laid down formal diagnostic criteria, which matters because the older literature is muddied by inconsistent inclusion definitions.

Key identifiers (⚠️ verify against OAK/OLS before curation — several are heterogeneous): - MONDO: MONDO:0016532 (Lennox-Gastaut syndrome) — verify in local sqlite:obo:mondo per the new-MONDO-term cache-miss memory note. - OMIM: 606369 is cross-referenced by GARD/Orphanet, but note that the live OMIM entry 606369 currently carries the title "Macrocephaly and Epileptic Encephalopathy" — OMIM does not maintain a single clean LGS phenotype entry because the syndrome is genetically heterogeneous. Individual genetic causes have their own DEE MIM numbers. Treat the OMIM mapping as soft. - Orphanet: ORPHA:2382 (confirmed). - ICD-10: G40.812 / G40.813 (intractable, with/without status epilepticus). ICD-11: 8A62.1 (approximate — verify). - MeSH: D065768 (Lennox Gastaut Syndrome). UMLS: C0520725.

Synonyms / alternative names: Lennox syndrome; Lennox-Gastaut-Dravet (obsolete lumping); "epileptic encephalopathy with slow spike-wave"; historically overlapped with "petit mal variant" and "childhood epileptic encephalopathy." It is distinct from — but often evolves out of — West syndrome / infantile spasms.

Data provenance. Information here is overwhelmingly disease-level aggregated (OMIM, Orphanet, ILAE consensus, systematic reviews, RCTs) rather than individual-patient/EHR. The main EHR-derived signals are the mortality and healthcare-utilization linkage cohorts (e.g., the German claims study).

2. Etiology

LGS is etiologically heterogeneous — the defining feature of the whole entry. Broadly, causes split into identifiable (symptomatic/secondary, ~65–75%) and unknown/cryptogenic (~25–35%, shrinking as genetic testing improves).

Disease causal factors (upstream tributaries): - Structural (the largest identifiable bucket): hypoxic-ischemic encephalopathy, cortical malformations (focal cortical dysplasia, lissencephaly, polymicrogyria, tuberous sclerosis tubers, hypothalamic hamartoma), congenital infections, stroke, trauma, tumors. - Genetic: de novo dominant variants in a long list of DEE genes (see §4). Over 900 monogenic causes of DEEs have been catalogued. - Metabolic/mitochondrial: inborn errors that present as DEE. - Prior epileptic encephalopathy: roughly 10–30% of LGS evolves from West syndrome/infantile spasms — a developmental trajectory rather than an independent cause.

Risk factors: - Genetic: a de novo pathogenic variant in an intolerant DEE gene (SCN2A, STXBP1, CHD2, GABRB3, ALG13, SCN8A, DNM1, etc.). Mostly not "susceptibility loci" in the GWAS sense — these are high-penetrance dominant lesions. - Environmental/perinatal: perinatal hypoxia, prematurity, CNS infection (meningitis/encephalitis), traumatic brain injury in early childhood. - Demographic: age (onset window 1–8 yr, peak 3–5), male sex (modest male predominance), and a prior history of infantile spasms.

Protective factors. No established genetic or dietary protective factors specific to LGS. The nearest analogues are treatment-induced (early seizure control, avoidance of seizure-aggravating drugs). Note: sodium-channel blockers such as carbamazepine, oxcarbazepine, phenytoin, and vigabatrin can worsen myoclonic/absence seizures in LGS — an "anti-protective" iatrogenic factor worth capturing.

Gene-environment interactions. Not well characterized as formal GxE. The relevant interaction is developmental-timing × lesion: the same structural or genetic insult produces LGS specifically when it perturbs the maturing thalamocortical network in the early-childhood window; the identical genotype/lesion at another age yields a different syndrome. This "network maturation state" gating is the closest thing to a GxE story.

3. Phenotypes

LGS is defined by its phenotype cluster. For each, HP-term suggestions and typical characteristics:

Core seizure phenotypes: | Phenotype | HPO suggestion | Notes / frequency | |---|---|---| | Seizures (overall) | HP:0001250 | ~100% (defining) | | Tonic seizures | HP:0032792 | Obligatory hallmark; often nocturnal; ~present in nearly all | | Atypical absence seizures | HP:0007270 | Very frequent (~60–90%) | | Atonic/astatic (drop) seizures | HP:0010819 | Frequent; cause injurious falls | | Myoclonic seizures | HP:0032794 / HP:0001336 | Common | | Generalized tonic-clonic seizures | HP:0002069 | Common | | Nonconvulsive status epilepticus | HP:0002133 (status epilepticus) | Occurs in ~50–75% at some point | | Falls / drop attacks | HP:0002527 | Major morbidity driver |

EEG phenotypes: - Generalized slow spike-and-wave (<2.5–3 Hz): HP:0010845 (EEG with generalized slow spike-and-wave complexes). - Generalized paroxysmal fast activity in sleep: closest is HP:0011198 / HP:0011197 (EEG with generalized epileptiform discharges) — no precise GPFA HP term exists; flag as an ontology gap. - Abnormally slow background rhythm.

Cognitive/behavioral phenotypes: - Intellectual disability: HP:0001249 (progressive; often severe by adolescence). - Global developmental delay: HP:0001263 (frequently precedes/accompanies onset). - Cognitive regression/plateau: HP:0100543 (cognitive impairment). - Behavioral abnormality: HP:0000708; autistic behavior HP:0000729; aggression HP:0000718; ADHD-like inattention/hyperactivity HP:0007018. - Sleep disturbance (recently reviewed as a major, under-recognized burden).

Phenotype characteristics: - Onset: childhood, typically 3–5 yr (range 1–8); onset before age 1 is atypical. - Severity: moderate-to-severe and largely fixed/progressive for cognition; seizure severity fluctuates but is chronically drug-resistant. - Progression: cognitive trajectory is progressive/regressive; seizure semiology evolves with age (tonic seizures may become more prominent in adolescence/adulthood; absences and drops may attenuate). - Frequency among affected: tonic seizures and cognitive impairment approach 100% (definitional); other seizure types are variably present.

Quality-of-life impact. Substantial and multidimensional — injurious drop attacks (fractures, dental/facial trauma, need for helmets), high caregiver burden, dependency, institutionalization risk, sleep disruption, and behavioral comorbidity. Systematic reviews (Orphanet J Rare Dis 2023) document heavy healthcare utilization and among the lowest QoL scores in pediatric epilepsy.

4. Genetic / Molecular Information

Framing: there is no single "LGS gene." LGS is a phenotypic convergence point; genetic testing yields a molecular diagnosis in a substantial minority, mostly de novo dominant variants.

Landmark evidence — the Epi4K exome study (Allen et al., Nature 2013, PMID: 23934111 ✅ verified): whole-exome trio sequencing of 264 probands (149 infantile spasms + 115 LGS) found de novo mutations enriched in genes intolerant to variation, with genome-wide-significant associations for GABRB3 and ALG13. De novo mutations were seen in ≥15% of the cohort.

Causal / recurrently implicated genes (de novo dominant unless noted): - Ion channels (channelopathies): SCN1A, SCN2A, SCN8A, KCNQ2, KCNA2, KCNT1, CACNA1A, HCN1. - GABA-A receptor subunits: GABRB3, GABRA1, GABRG2 — directly implicate inhibitory neurotransmission. - Synaptic / vesicle-trafficking (synaptopathies): STXBP1, DNM1, IQSEC2. - Neuronal migration / cortical development: DCX, FLNA, ARX, LIS1(PAFAH1B1). - mTOR pathway: MTOR, TSC1/TSC2 (tuberous sclerosis), DEPDC5. - Chromatin / epigenetic regulators: CHD2 (≥11 de novo variants reported in DEE incl. LGS), plus others. - Glycosylation / metabolic: ALG13, SLC25A39, and others. - Additional single-case reports (e.g., TANC2 truncating variant, PMID from 2021 case report; NRG2, DNAJC5).

Variant characteristics: - Classification: pathogenic/likely pathogenic per ACMG/AMP (check ClinVar/ClinGen per gene). - Type: predominantly missense and protein-truncating (nonsense/frameshift/splice); also copy-number/structural (via chromosomal microarray). - Allele frequency: de novo variants are absent from population databases (gnomAD) — that absence is part of their pathogenicity argument. - Origin: overwhelmingly germline de novo (arising in parental gametes/early embryo); not inherited in most cases — key genetic-counseling point. - Functional consequence: mixed — loss of function (GABRB3, STXBP1, DNM1, CHD2 haploinsufficiency), gain of function (some SCN2A/SCN8A), and dominant-negative (some GABA-A subunit variants). The GABRB3 N328D knock-in mouse (PMC10179596) is a functional model that reproduces an LGS-like phenotype.

Modifier genes: not systematically defined; the genetic background modulating penetrance/expressivity is an open question.

Epigenetic information: CHD2 (chromodomain helicase) links LGS to chromatin remodeling dysregulation; broader disease-specific methylation signatures are not established. (Search-first: ENCODE, Roadmap.)

Chromosomal abnormalities: chromosomal microarray detects pathogenic CNVs in a subset; large structural lesions and ring chromosome 20 are associated with LGS-like phenotypes (ring 20 classically mimics LGS with nonconvulsive status).

Suggested GO/gene annotations: GABA signaling GO:0007214; regulation of GABAergic synaptic transmission GO:0032228; synaptic vesicle exocytosis GO:0016079; sodium ion transmembrane transport GO:0035725; potassium ion transmembrane transport GO:0071805; neuron migration GO:0001764; TOR signaling GO:0031929; chromatin remodeling GO:0006338. HGNC IDs to bind (lowercase hgnc: per repo convention): SCN2A, STXBP1, CHD2, GABRB3, SCN8A, DNM1, KCNQ2, MTOR, ALG13, etc.

5. Environmental Information

Environmental factors: perinatal hypoxia-ischemia is the most important; also CNS infection (bacterial meningitis, viral encephalitis), traumatic brain injury, and any early-childhood cortical insult. No specific toxin/pollutant is causally established.
Lifestyle factors: not applicable as causes (this is a pediatric encephalopathy); relevant lifestyle domain is management — sleep hygiene, seizure-trigger avoidance, and dietary therapy (§12).
Infectious agents: not a primary infectious disease, but congenital/early CNS infections are among the acquired structural causes. Some cases follow encephalitis. No single pathogen is definitional. (NCBI Taxonomy: not applicable as a defining agent.)

6. Mechanism / Pathophysiology

The unifying model — secondary network epilepsy. The convergent-endpoint view (Archer/Warren and colleagues; Front Neurol 2014, PMID: 24902608; Neurology 2019 "The epileptic network of LGS") holds that regardless of the initiating lesion, LGS manifests through a distributed thalamocortical–brainstem network whose stereotyped failure produces the slow spike-wave and tonic phenomena.

Causal chain (trigger → manifestation): 1. Initiating insult (structural lesion, de novo channel/synaptic/chromatin variant, prior IS) perturbs the developing cortex. 2. Aberrant network maturation — failure of normal synaptic pruning → cortical hyperconnectivity and pathological network behavior; excitation/inhibition imbalance from GABAergic/glutamatergic dysfunction. 3. Secondary bilateral synchrony — focal/multifocal cortical hyperexcitability recruits the whole network, generating generalized slow spike-wave and GPFA discharges. This is why a focal cortical lesion can produce a "generalized"-looking syndrome, and why removing that lesion can abolish the whole process. 4. Thalamus as synchronizer/amplifier, not initiator — EEG-fMRI shows interictal discharges activate brainstem and centromedian/anterior thalamic nuclei; the prefrontal/premotor and frontoparietal association cortices are the peak hubs (bilateral premotor cortex / caudal middle frontal gyrus per fMRI; frontoparietal FDG-PET hypometabolism). This is the rationale for thalamic (centromedian) closed-loop and DBS neuromodulation (Brain Communications 2024, fcae161). 5. Clinical output — multiple generalized seizure types + progressive encephalopathy from chronic network disruption during a critical developmental period.

Molecular pathways / cellular processes: - GABAergic inhibition failure (GABRB3/GABRA1/GABRG2; GABA-A receptor CHEBI:16865 GABA) → reduced inhibitory tone. - Ion-channel dysfunction (SCN2A/SCN8A Nav, KCNQ2/KCNA2/KCNT1 Kv/KNa) → altered GO:0042391 regulation of membrane potential and neuronal firing. - Synaptic vesicle/exocytosis defects (STXBP1, DNM1) → impaired GO:0007268 chemical synaptic transmission. - mTOR hyperactivation (TSC/MTOR) → dysplastic, hyperexcitable cortex (GO:0031929). - Chromatin dysregulation (CHD2) → altered neurodevelopmental gene expression.

Protein dysfunction: loss of function (haploinsufficiency of GABRB3/STXBP1/CHD2), gain of function (Nav channels), dominant-negative (some GABA-A subunits). (UniProt/AlphaFold for structural detail.)

Metabolic changes: frontoparietal glucose hypometabolism on FDG-PET is a robust network signature; specific inborn errors underlie the metabolic-etiology subset. The ketogenic diet's efficacy implicates cerebral energy metabolism shift toward ketone utilization as a therapeutic lever.

Immune involvement: not a primary immune-mediated epilepsy; neuroinflammation is a general seizure-associated process, not a defining mechanism.

Cell types / anatomy (for annotation): - Cell types (CL): neuron CL:0000540, GABAergic interneuron CL:0000617, glutamatergic/pyramidal neuron CL:0000598/CL:0000679, thalamocortical projection neurons. - Anatomy (UBERON): brain UBERON:0000955, cerebral cortex UBERON:0000956, frontal lobe UBERON:0001870, thalamus UBERON:0001897, brainstem UBERON:0002298, corpus callosum UBERON:0002336. (Centromedian thalamic nucleus may lack a precise UBERON term — flag.)

Molecular profiling / advanced tech: most mechanistic traction is from EEG-fMRI, FDG-PET, and network connectivity rather than omics; single-cell/spatial transcriptomic LGS-specific data are sparse. GABRB3 N328D knock-in mice provide the cleanest functional-genomics model.

7. Anatomical Structures Affected

Organ level: brain (primary); nervous system is the sole primary system. Secondary/whole-body effects are consequences of drops (musculoskeletal injury) and chronic disability (respiratory — aspiration; nutritional).
Body systems: central nervous system primarily; secondary musculoskeletal (fall injuries), respiratory (aspiration pneumonia, a leading cause of death), and psychiatric/behavioral.
Tissue/cell level: cortical gray matter (association cortex), thalamic nuclei, brainstem; affected populations are cortical/thalamic neurons and GABAergic interneurons (CL:0000617).
Subcellular level (GO Cellular Component): synapse GO:0045202, presynaptic/postsynaptic membranes, ion-channel complexes at the plasma membrane, synaptic vesicle GO:0008021.
Localization: bilateral, diffuse but frontally/frontoparietally predominant; the network is bilateral and largely symmetric (secondary bilateral synchrony), even when the initiating lesion is unilateral/focal.

8. Temporal Development

Onset: pediatric, typically ages 1–8 (peak 3–5); insidious/subacute, often emerging after or alongside developmental delay, sometimes evolving from West syndrome (~10–30%).
Progression / stages: early phase (emerging multiple seizure types + slowing EEG) → established phase (full triad, tonic seizures dominant, cognitive regression) → adult phase (seizures persist; semiology shifts, tonic seizures and status remain; drops/absences may lessen).
Course: chronic, lifelong, drug-resistant; not relapsing-remitting — persistent with fluctuating seizure burden.
Remission: spontaneous remission is rare (~80–90% continue to have seizures into adulthood). Treatment reduces but rarely abolishes seizures.
Critical period: the early-childhood developmental window is both the vulnerability window and the intervention window — early seizure control is thought to matter for developmental outcome, though drug resistance blunts this.

9. Inheritance and Population

Epidemiology (from Sullivan et al. systematic review, Epilepsia 2024, and burden-of-illness reviews): - Incidence: ~14.5–28 per 100,000 (context-dependent — some figures are cumulative childhood incidence, interpret carefully). - Prevalence: ~5.8–60.8 per 100,000 for probable LGS; ~2.9–28 per 100,000 for narrow/confirmed definitions. Enriched in intellectual-disability populations (~7%, up to ~16% institutionalized). - LGS accounts for 1–4% of all childhood epilepsy but ~10% of epilepsy with onset before age 5.

Genetic epidemiology: - Inheritance pattern: predominantly sporadic / de novo dominant; not classically Mendelian-inherited. A minority reflect inherited structural/metabolic conditions (e.g., tuberous sclerosis = AD; some X-linked genes ALG13, IQSEC2, CDKL5, DCX, FLNA). - Penetrance/expressivity: de novo DEE variants are generally high-penetrance but variably expressive (same gene → different DEE syndromes). - Anticipation: not applicable (not a repeat-expansion disorder). - Germline mosaicism: possible (relevant to recurrence-risk counseling) but low recurrence overall. - Founder effects / consanguinity / carrier frequency: generally not applicable given the de novo/sporadic nature; consanguinity matters only for the rare AR metabolic causes.

Demographics: - Sex ratio: modest male predominance (boys > girls). - Ethnicity/geography: no established ethnic or geographic predilection. - Age distribution: childhood-onset with a lifelong prevalent adult population (survivors persist into adulthood).

10. Diagnostics

Diagnosis is electroclinical — the ILAE 2022 criteria formalize it.

Core diagnostic tests: - EEG (defining): interictal slow spike-and-wave <2.5–3 Hz on a slow background; sleep-activated generalized paroxysmal fast activity (GPFA), the near-specific correlate of tonic seizures. Ictal EEG for tonic/atonic/atypical-absence events. (LOINC: EEG panels.) - Video-EEG / prolonged monitoring to capture the multiple seizure types. - Brain MRI: to identify structural etiology (malformations of cortical development, hypoxic injury, tubers). (RadLex/Radiopaedia.) - FDG-PET: frontoparietal hypometabolism (supportive/network, not diagnostic).

Etiologic workup (genetic testing): - Chromosomal microarray (CMA) for CNVs; karyotype/FISH for ring chromosome 20 and other structural anomalies. - Epilepsy gene panels / whole-exome sequencing (WES) — highest yield; trio WES best for de novo detection. Whole-genome sequencing (WGS) increasingly used. - Metabolic workup / mitochondrial testing when metabolic etiology suspected. - GeneReviews / GTR / ClinGen for gene-level interpretation.

Clinical criteria: ILAE 2022 syndrome definition requires the seizure-type + EEG + cognitive triad, with tonic seizures and/or GPFA carrying strong diagnostic weight.

Differential diagnosis (key mimics to rule out): - Epilepsy with myoclonic-atonic seizures (Doose syndrome) — myoclonic-atonic predominant, better prognosis, no tonic seizures/GPFA. - Dravet syndrome — SCN1A, fever-sensitive, earlier onset. - Atypical benign partial epilepsy / pseudo-Lennox — better outcome. - Ring chromosome 20 epilepsy, continuous spike-wave in slow sleep (CSWS), West syndrome (may precede LGS).

Screening. No population newborn screen for LGS itself; relevant genetic causes may surface on expanded newborn screening or carrier screening only for the specific metabolic/monogenic subset.

11. Outcome / Prognosis

Prognosis is unfavorable but variable. ~80–90% continue to have seizures into adulthood; cognitive impairment is usually permanent and often progressive.
Mortality: significantly elevated vs. general population. A German linkage cohort reported ~2.88% mortality over 10 years vs. ~0.01% in age-matched controls — an ~orders-of-magnitude excess. Causes include SUDEP (sudden unexpected death in epilepsy), status epilepticus, aspiration pneumonia, and injury from drop attacks.
Morbidity/disability: severe — intellectual disability, dependency, injurious falls, behavioral comorbidity, high institutionalization rate. Among the highest disability burdens in pediatric epilepsy (GBD/ICF framing).
Prognostic factors (worse outcome): early onset, evolution from West syndrome, symptomatic/structural etiology, high tonic-seizure and status frequency, early cognitive impairment. Cryptogenic cases with later onset and no prior IS tend to fare relatively better.
QoL measures: disease-specific and generic tools (caregiver-reported) consistently show low scores; drop-seizure frequency is a key modifiable QoL driver (hence trial endpoints focus on drops).

12. Treatment

Goal: seizure-burden reduction (especially injurious drops) and QoL — not cure. Polytherapy is the norm; drug resistance is expected.

Pharmacotherapy — FDA-approved for LGS (8 agents; approval years): clonazepam (1975), felbamate (1993), lamotrigine (1998), topiramate (2001), rufinamide (2008), clobazam (2011), cannabidiol (2018), fenfluramine (2022). Valproic acid is common first-line broad-spectrum background therapy (widely used, not LGS-labeled).

Landmark trial evidence (verified): - Cannabidiol (Epidiolex), CHEBI:69478 — GWPCARE4 (Thiele et al., Lancet 2018, PMID: 29395273 ✅) and GWPCARE3 (Devinsky et al., NEJM 2018, PMID: 29768152 ✅): add-on CBD significantly reduced drop-seizure frequency vs. placebo; 2024 consensus panel (Epilepsia Open) optimizes dosing. Modality: SMALL_MOLECULE (phytocannabinoid). - Fenfluramine (Fintepla), CHEBI:5000 — Knupp et al., JAMA Neurol 2022;79(6):554–564, PMID: 35499850 ✅ verified: RCT, n=263; 0.7 mg/kg/d gave 26.5% median drop-seizure reduction vs. 7.6% placebo (P=.001); no valvular heart disease or pulmonary hypertension observed. Open-label extension (Knupp, Epilepsia 2023, PMID: 36196777 ✅) confirmed durable benefit. - Rufinamide, CHEBI:32219 — pivotal RCT (Glauser et al., Neurology 2008) established efficacy for drop attacks. ⚠️ PMID from memory ~18936427/18401024 — verify with just fetch-reference before curation. - Lamotrigine — Motte et al., NEJM 1997. ⚠️ Verify PMID. - Felbamate — Felbamate Study Group, NEJM 1993 (efficacy strong but limited by aplastic anemia/hepatotoxicity risk). ⚠️ Verify PMID. - Topiramate — Sachdeo et al., Neurology 1999. ⚠️ Verify PMID. - Clobazam, CHEBI:31401 — Ng et al., Neurology 2011 (pivotal). ⚠️ Verify PMID.

Emerging / off-label pharmacotherapy: - Cenobamate — retrospective/real-world adult and pediatric LGS series show meaningful drop-seizure reduction and enable clobazam dose reduction (PMC9821211, PMC12255617, 2023–2024). Not yet LGS-labeled. - Soticlestat (CH24H inhibitor) — phase-3 signal in LGS was a nonsignificant numerical reduction in drops (contrast with positive Dravet data); development context evolving. - Low-dose fenfluramine in adults (PMC12317795, 2024). - 2024 consensus treatment algorithm published (Epilepsy & Behavior, S1525-5050(24)00643-7).

Pharmacogenomics: relevant at the drug-safety level — e.g., HLA-linked risk for lamotrigine cutaneous reactions (SJS/TEN); CYP-mediated clobazam metabolism (CYP2C19). Emerging precision therapy matches the molecular etiology to mechanism (e.g., sodium-channel-blocker avoidance in some, targeted approaches for mTOR/GABA-A variants). (IJMS 2025 precision-therapeutics review, PMC12025602.)

Non-pharmacologic / interventional: - Ketogenic diet (MAXO:0000088 dietary intervention as fallback term; check for a specific MAXO ketogenic term): ~50% of patients achieve >50% seizure reduction; some >90%. - Vagus nerve stimulation (VNS): ~50% responder rate (>50% reduction), improving over time; palliative. - Corpus callosotomy (MAXO:0000004 surgical procedure): most effective option for injurious drop attacks — disconnects interhemispheric spread. Systematic review/meta-analysis supports callosotomy + diet efficacy (Child's Nerv Syst 2021). - Thalamic (centromedian) DBS / closed-loop stimulation: emerging neuromodulation targeting the network hub (Brain Communications 2024). - Resective surgery when a focal structural lesion drives the network. - Supportive/rehabilitative: helmets for drop protection, PT/OT/speech (MAXO:0000950 supportive care; NCIT:C15315 rehabilitation), behavioral and sleep management.

Advanced therapeutics (experimental): gene-targeted/ASO approaches are on the horizon for specific monogenic causes (STXBP1, SCN2A, etc.) but not yet LGS-syndrome therapies. ClinicalTrials.gov (e.g., NCT03936777 fenfluramine long-term safety) for active programs.

MAXO/NCIT term suggestions: pharmacotherapy NCIT:C15986 (with therapeutic_agent CHEBI drugs); dietary intervention MAXO:0000088; surgical procedure MAXO:0000004; supportive care MAXO:0000950; genetic counseling MAXO:0000079. VNS and ketogenic-diet-specific MAXO terms should be looked up with OAK.

13. Prevention

Primary prevention: limited — reduce acquired causes via good perinatal care (preventing hypoxic-ischemic injury), CNS-infection prevention/vaccination, and TBI prevention. No vaccine or lifestyle intervention prevents LGS directly.
Secondary prevention: early recognition and control of infantile spasms/West syndrome may reduce evolution to LGS (an active hypothesis and management priority); early EEG in a child with developmental delay + new seizures for prompt diagnosis.
Tertiary prevention (complication avoidance): the practical core — drop-injury prevention (helmets, callosotomy), SUDEP-risk mitigation (seizure control, nocturnal monitoring), aspiration/nutrition management, avoiding seizure-aggravating ASMs (carbamazepine, oxcarbazepine, phenytoin, vigabatrin).
Genetic counseling (MAXO:0000079): for families with an identified de novo variant, recurrence risk is generally low (low-level germline mosaicism caveat); for inherited causes (TSC, X-linked genes) counseling is more consequential. Prenatal/preimplantation testing applies only when a specific familial variant is known.
Screening: no population screen; cascade/prenatal testing only for the monogenic/structural subset.

14. Other Species / Natural Disease

Taxonomy: LGS as a defined electroclinical syndrome is essentially human-specific (NCBITaxon:9606). There is no recognized naturally occurring LGS in other species (OMIA has no LGS entry).
Comparative biology: the mechanisms are conserved — epilepsy and the underlying channel/synaptic genes have clear orthologs. Mouse models of specific genes (GABRB3, SCN2A, etc.) recapitulate seizure/encephalopathy features but not the full human syndrome (human association-cortex network complexity isn't reproduced).
Zoonotic potential: none (non-infectious, non-transmissible).

This section is largely N/A — LGS is a human network-epilepsy syndrome; the comparative angle lives entirely in the model-organism domain below.

15. Model Organisms

Model types: predominantly mammalian (mouse) gene-specific models; also zebrafish for channel/high-throughput drug screening; iPSC-derived neurons/organoids for synaptic phenotyping; in vitro electrophysiology of variant channels/receptors.
Genetic models: knock-in (point-mutation), knockout, and conditional/humanized alleles of DEE genes.
Flagship example: GABRB3 N328D heterozygous knock-in mouse (PMC10179596) — reproduces an LGS-like phenotype (multiple seizure types, EEG abnormalities, behavioral/cognitive deficits), one of the better syndrome-level recapitulations. Other models: Scn2a, Scn8a, Stxbp1, Dnm1 (fitful mouse), Chd2, Cdkl5, Alg13 mice — each captures a slice of the phenotype.
Phenotype recapitulation: single-gene models reproduce seizures, EEG discharges, and neurodevelopmental deficits, and are used for mechanism and drug testing. Limitation: none fully reproduces the human syndrome's distributed frontoparietal network dysfunction and cognitive regression — a HUMAN_MODEL_MISMATCH-flavored gap worth flagging in the KB (evidence exists in models but the network-level, association-cortex biology is human-specific).
Applications: genotype-specific pathophysiology, ASM screening, precision-therapy proof-of-concept (e.g., gene-targeted approaches).
Resources: MGI, IMPC/KOMP, ZFIN, Alliance of Genome Resources; Cellosaurus for iPSC lines.

Curation notes & caveats for the KB entry

Evidence-source tagging: the RCTs (fenfluramine, CBD) are HUMAN_CLINICAL; the GABRB3 N328D mouse is MODEL_ORGANISM; variant-channel electrophysiology is IN_VITRO; network/PET modeling papers are HUMAN_CLINICAL or COMPUTATIONAL depending on method. Keep model-organism evidence distinct from human phenotype claims.
Verified PMIDs (safe to seed): 23934111 (Epi4K), 35499850 (fenfluramine RCT), 36196777 (fenfluramine OLE), 29395273 (CBD GWPCARE4), 29768152 (CBD GWPCARE3), 24902608 (secondary network epilepsy).
PMIDs to verify before use (from memory): the older ASM pivotal trials (rufinamide/Glauser, lamotrigine/Motte, felbamate, topiramate/Sachdeo, clobazam/Ng). Run just fetch-reference and confirm exact-quote snippets — don't trust my recalled numbers.
Identifier flags: MONDO:0016532 (verify via local sqlite:obo:mondo; watch the OLS cache-miss issue), OMIM 606369 is a soft/heterogeneous mapping, ORPHA:2382 confirmed.
Ontology gaps to note: no precise HP term for generalized paroxysmal fast activity; centromedian thalamic nucleus may lack a UBERON term; ketogenic-diet/VNS MAXO terms need OAK lookup.
Module conformance opportunity: LGS is a natural conformer for epilepsy_excitation_inhibition_imbalance (key node #Excitation-Inhibition Imbalance) — the E/I-imbalance → hyperexcitability → seizure chain maps cleanly, with LGS substituting the secondary-bilateral-synchrony/thalamocortical-network specialization.

Primary sources drawn on: - Allen et al., De novo mutations in epileptic encephalopathies, Nature 2013 (PMID 23934111) - Knupp et al., Fenfluramine RCT in LGS, JAMA Neurol 2022 (PMID 35499850) - Knupp et al., Fenfluramine OLE, Epilepsia 2023 (PMID 36196777) - Thiele et al., Cannabidiol GWPCARE4, Lancet 2018 (PMID 29395273) - Devinsky et al., Cannabidiol GWPCARE3, NEJM 2018 (PMID 29768152) - Archer et al., LGS as secondary network epilepsy, Front Neurol 2014 (PMID 24902608) - Sullivan et al., Global epidemiology of Dravet & LGS, Epilepsia 2024 - Burden of illness in LGS systematic review, Orphanet J Rare Dis 2023 - Precision Therapeutics in LGS, IJMS 2025 (PMC12025602) - GABRB3 N328D knock-in mouse LGS model (PMC10179596) - Targeting thalamocortical circuits for closed-loop stimulation in LGS, Brain Commun 2024 - Orphanet: Lennox-Gastaut syndrome (ORPHA:2382) - Diagnosis of LGS and early recognition, Expert Rev Neurother 2024

That's the whole delta mapped — tributaries, the swampy convergence point, and the levees we've got to hold it back. The single most load-bearing idea for the KB is that "cause" and "syndrome" live at different altitudes here: curate the many upstream etiologies as distinct genetic/structural nodes, but let them all drain into the shared secondary-network-epilepsy mechanism. Want me to go ahead and scaffold the actual kb/disorders/Lennox-Gastaut_Syndrome.yaml entry from this, or run the MONDO/OMIM identifier verification first?

Ask OpenScientist

OpenScientist Report

Mappings

Discussions and Knowledge Gaps

Pathophysiology

Pathograph

Phenotypes

Genetic Associations

Medical Actions

Source YAML

References & Deep Research

Deep Research

1. Disease Information

2. Etiology

3. Phenotypes

4. Genetic / Molecular Information

5. Environmental Information

6. Mechanism / Pathophysiology

7. Anatomical Structures Affected

8. Temporal Development

9. Inheritance and Population

10. Diagnostics

11. Outcome / Prognosis

12. Treatment

13. Prevention

14. Other Species / Natural Disease

15. Model Organisms

Curation notes & caveats for the KB entry